Literature DB >> 33890476

Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.

Laura D'Erasmo1, Ilenia Minicocci1, Alessia Di Costanzo1, Giovanni Pigna1, Daniela Commodari1, Fabrizio Ceci2, Anna Montali1, Francesca Brancato1, Ilaria Stanca1, Antonio Nicolucci3, Andrea Ascione4, Nicola Galea4, Iacopo Carbone5, Marco Francone4, Marianna Maranghi1, Marcello Arca1.   

Abstract

Background Familial hypercholesterolemia (FH) may arise from deleterious monogenic variants in FH-causing genes as well as from a polygenic cause. We evaluated the relationships between monogenic FH and polygenic hypercholesterolemia in influencing the long-term response to therapy and the risk of atherosclerosis. Methods and Results A cohort of 370 patients with clinically diagnosed FH were screened for monogenic mutations and a low-density lipoprotein-rising genetic risk score >0.69 to identify polygenic cause. Medical records were reviewed to estimate the response to lipid-lowering therapies and the occurrence of major atherosclerotic cardiovascular events during a median follow-up of 31.0 months. A subgroup of patients (n=119) also underwent coronary computed tomographic angiography for the evaluation of coronary artery calcium score and severity of coronary stenosis as compared with 135 controls. Two hundred nine (56.5%) patients with hypercholesterolemia were classified as monogenic (FH/M+), 89 (24.1%) as polygenic, and 72 (19.5%) genetically undefined (FH/M-). The response to lipid-lowering therapy was poorest in monogenic, whereas it was comparable in patients with polygenic hypercholesterolemia and genetically undetermined. Mean coronary artery calcium score and the prevalence of coronary artery calcium >100 units were significantly higher in FH/M+ as compared with both FH/M- and controls. Finally, after adjustments for confounders, we observed a 5-fold higher risk of incident major atherosclerotic cardiovascular events in FH/M+ (hazard ratio, 4.8; 95% CI, 1.06-21.36; Padj=0.041). Conclusions Monogenic cause of FH is associated with lower response to conventional cholesterol-lowering therapies as well as with increased burden of coronary atherosclerosis and risk of atherosclerotic-related events. Genetic testing for hypercholesterolemia is helpful in providing important prognostic information.

Entities:  

Keywords:  atherosclerosis; cardiovascular disease; genetics; hypercholesterolemia; therapy

Year:  2021        PMID: 33890476     DOI: 10.1161/JAHA.120.018932

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  4 in total

Review 1.  Monogenic Versus Polygenic Forms of Hypercholesterolemia and Cardiovascular Risk: Are There Any Differences?

Authors:  Erin Jacob; Robert A Hegele
Journal:  Curr Atheroscler Rep       Date:  2022-04-07       Impact factor: 5.113

2.  Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.

Authors:  Vittoria Cammisotto; Francesco Baratta; Valentina Castellani; Simona Bartimoccia; Cristina Nocella; Laura D'Erasmo; Nicholas Cocomello; Cristina Barale; Roberto Scicali; Antonino Di Pino; Salvatore Piro; Maria Del Ben; Marcello Arca; Isabella Russo; Francesco Purrello; Roberto Carnevale; Francesco Violi; Daniele Pastori; Pasquale Pignatelli
Journal:  Int J Mol Sci       Date:  2021-07-03       Impact factor: 5.923

Review 3.  How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?

Authors:  Yu Kataoka; Sayaka Funabashi; Takahito Doi; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2022-01-13       Impact factor: 4.394

4.  Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations.

Authors:  Elena Olmastroni; Marta Gazzotti; Marcello Arca; Maurizio Averna; Angela Pirillo; Alberico Luigi Catapano; Manuela Casula
Journal:  J Am Heart Assoc       Date:  2022-03-24       Impact factor: 6.106

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.